about
Taking forward a ‘ONE HEALTH’ approach for turning the tide against The Middle East Respiratory Syndrome Coronavirus and other zoonotic pathogens with epidemic potentialPeptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisB in TB: B Cells as Mediators of Clinically Relevant Immune Responses in TuberculosisT-Cell Therapy: Options for Infectious DiseasesThe immunological footprint of Mycobacterium tuberculosis T-cell epitope recognitionLearning from epidemiological, clinical and immunological studies on Mycobacterium africanum for improving current understanding of host-pathogen interactions, and for the development and evaluation of diagnostics, host-directed therapies and vaccReduced T-cell receptor CD3zeta-chain protein and sustained CD3epsilon expression at the site of mycobacterial infectionEvaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with non-communicable diseases in sputum producing adult inpatientsTuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy.The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications.A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010.Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 influenza pandemicRapid point of care diagnostic tests for viral and bacterial respiratory tract infections--needs, advances, and future prospects.H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.Increased β-haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases.Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients.A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden.Taking forward the World TB Day 2016 theme 'Unite to End Tuberculosis' for the WHO Africa Region.Drug-resistant tuberculosis: time for visionary political leadership.Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis.Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection.Validation of peptide epitope microarray experiments and extraction of quality data.Diagnosing Helicobacter pylori in vivo by confocal laser endoscopy.rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vectorPattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosisIdentification of MHC class II binding peptides: microarray and soluble MHC class II molecules.Increased numbers of IL-7 receptor molecules on CD4+CD25-CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system.Use of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, ZambiaReduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults.Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor.Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus.Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs.Short communication: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in AfricaDifferential cellular recognition pattern to M. tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from HondurasA broad profile of co-dominant epitopes shapes the peripheral Mycobacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis.The T-cell response in patients with cancer.
P50
Q24635959-09B26FD3-D9C9-4E1C-A265-A2771B72019AQ24656969-038A17C5-89A3-464C-A7E1-53CB8BAB5BA2Q26746099-D990647D-6384-41DA-A3E5-89AE5D571170Q26786655-640433CD-B1C6-45D4-ADB5-77C8F0B7ED24Q26786661-2BA4C118-0E9A-403D-BB82-75D0DB6E18F4Q27021375-E1A466E4-4DEF-4175-A425-B7C165F1AB63Q28078580-B73BB7DB-A91E-4AC3-885F-17E6A77FAB43Q28365225-E184E74C-D09B-4F71-BC03-F0B52A529190Q28481629-22D17BDA-BD12-4748-B994-0CF19141F072Q30236019-A81FB04D-11C8-432F-8493-9CB2DBBDD823Q30236033-D06C0D5B-E8DD-4CF2-84C7-D3786E303F4BQ30358564-BFAAB656-DE07-4A58-AA83-B608D73EB3BAQ30361227-987DD6B4-3737-49B4-AED1-E4D739334629Q30363471-704EFF10-AA05-43A5-9808-6B0BBB3919D0Q30366437-5533AA2A-D3F4-469A-BF64-D819C14F9721Q30371297-53D09996-4BAA-4867-9E59-61CF7C1CC4CCQ30371742-C55851D0-EC37-4926-BE84-49F4578CE58EQ30372939-C010AD95-3864-498A-A305-760473F96D15Q30373149-B8BAACC0-F2C3-41E8-8B64-7662AC089231Q30376157-A2509473-485A-4DCB-BAB6-1D5B8458561EQ30385577-45363576-1DEE-4D25-B9CC-176C5C2723BBQ30428762-074ADCE7-F10E-4175-8F61-1A1ABCAC52D4Q30459034-4C47ACCE-2F3C-4056-B185-5C6DA682BA1CQ30656264-CD08040F-4F95-48A9-82F7-E357CFA0CCCBQ30777647-24690405-2E85-4D1F-B3EB-150D8BA28A89Q31123855-B3322811-33A6-41E5-9C8B-A2C0572F2D40Q33216604-0A8C25C1-383D-4615-A19B-C52DDE6EA81DQ33386020-9D58F992-B637-431B-A629-1B39FABC68B4Q33391074-B75C1911-B682-403C-A4DD-31F423BBD2E6Q33432025-4AF00377-1986-4FD1-8299-DBA0CB42BBCFQ33490992-3BB3EDED-040E-45FA-886C-7D0FA1162290Q33593613-01DDEBEC-34BC-4433-854F-FE14BEC8571AQ33817588-4BE2D979-4445-40CD-ABC6-636E86F38533Q33942149-D57F7BF5-A589-4B9D-A16A-B020C3A80D29Q34159493-5307552B-CAF6-4507-B086-25922A58F183Q34266001-EC887D92-8EB6-4417-B4D5-42F2D6F2C369Q34399680-C3BA3286-A016-44B6-8241-C2001B385802Q34623344-FAA249D4-7152-4FA9-90B0-BE80E7833748Q34650335-708CBD4E-72FD-433F-A462-09803C4145B4Q34956078-7F54F5D5-E08A-4AE7-9718-0A0F01C3B10B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Markus Maeurer
@ast
Markus Maeurer
@en
Markus Maeurer
@es
Markus Maeurer
@nl
Markus Maeurer
@sl
type
label
Markus Maeurer
@ast
Markus Maeurer
@en
Markus Maeurer
@es
Markus Maeurer
@nl
Markus Maeurer
@sl
prefLabel
Markus Maeurer
@ast
Markus Maeurer
@en
Markus Maeurer
@es
Markus Maeurer
@nl
Markus Maeurer
@sl
P106
P1153
7004422039
P21
P31
P496
0000-0002-8436-8077